A recent study of patients with normal ALTs concluded that these patients should be treated with high doses of
IFN if they have a favorable response (Hepatogastroenterology. 2003 Jan-Feb;50(49):165-9).
There have been many studies, mostly in non-responders, with high doses of interferon, either at the beginning
of therapy (induction doses) or during therapy itself. The side effects are greater, and more people drop out of these trials.
Studies are being done with consensus interferon in high doses (
High Dose Censensus Interferon in Peg-IFN/Ribavirin Nonresponders, Reported by Jules Levin.)